US Pharma MarketingExclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
TwoStep raised a $62.5M Series A backed by Pfizer and Merck KGaA Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking…
Pfizer and Merck KGaA's venture groups are backing a nimble cancer startup taking a different approach to the popular antibody-drug conjugate and radioligand fields.
TwoStep Therapeutics collected $62.5 million in a Series A raise to ...
Source: Endpoints News